Aclaris Therapeutics, Inc.

Contributing Author

Recent Articles by Aclaris Therapeutics, Inc.

3 hours	Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference ACRS GlobeNewswire
Aug-06	Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) ACRS GlobeNewswire
Aug-06	Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) ACRS GlobeNewswire
Aug-06	Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update ACRS GlobeNewswire
May-28	Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference ACRS GlobeNewswire
May-08	Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference ACRS GlobeNewswire
May-07	Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update ACRS GlobeNewswire
Apr-28	Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor ACRS GlobeNewswire
Apr-27	Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 ACRS GlobeNewswire
Apr-08	Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference ACRS +5.33% GlobeNewswire
Mar-27	Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 ACRS GlobeNewswire
Mar-20	Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting ACRS GlobeNewswire
Mar-18	Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis ACRS -5.67% GlobeNewswire
Mar-03	Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference ACRS GlobeNewswire
Feb-26	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update ACRS -5.44% GlobeNewswire
Feb-24	Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Ra Antibody ATI-052 ACRS GlobeNewswire
Feb-04	Aclaris Therapeutics to Participate in Two February Healthcare Conferences ACRS GlobeNewswire
Jan-27	Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) ACRS GlobeNewswire
Jan-12	Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 ACRS GlobeNewswire
Jan-06	Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Supporting Expedited Clinical Development ACRS GlobeNewswire
Dec-19	Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) ACRS GlobeNewswire
Nov-25	Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference ACRS GlobeNewswire
Nov-06	Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update ACRS GlobeNewswire
Oct-29	Aclaris Therapeutics to Participate in Three November Healthcare Conferences ACRS GlobeNewswire
Sep-30	Aclaris Therapeutics to Host In-Person and Webcast R&D Day, "Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets", in New York on October 14, 2025 ACRS GlobeNewswire
Sep-09	Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress ACRS GlobeNewswire
Aug-27	Aclaris Therapeutics to Participate in Two September Healthcare Conferences ACRS GlobeNewswire
Aug-07	Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update ACRS GlobeNewswire
Jul-29	Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints ACRS -7.74% GlobeNewswire
Jul-28	Aclaris Therapeutics Announces Leadership Transition ACRS GlobeNewswire
Jun-30	Aclaris Therapeutics Added to the Russell 2000 and Russell 3000 Indexes ACRS GlobeNewswire
Jun-26	Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference ACRS ACRS -5.77% GlobeNewswire
Jun-23	Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052 ACRS GlobeNewswire
Jun-02	Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis ACRS GlobeNewswire
May-28	Aclaris Therapeutics to Participate in Two June Healthcare Conferences ACRS +11.02% GlobeNewswire
May-09	Aclaris Therapeutics to Participate in the HC Wainwright "HCW@Home" Series ACRS GlobeNewswire
May-08	Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update ACRS GlobeNewswire

Aclaris Therapeutics, Inc.

Recent Articles by Aclaris Therapeutics, Inc.

Upgrade your Finviz experience